1. History and mission
In order to foster the translation of outstanding scientific discoveries into new therapies for patients and breakthrough innovations in the fields of regenerative medicine, in 2015, Wyss Zurich, biotechnet and the NTN SwissBiotech founded a novel platform namend "Regenerative Medicine".
In order to sharpen and re-define its activities and competencies, the name of the platform has been redefined from "Regenerative Medicine" towards "Translational and Clinical Bio-Manufacturing (TCBM)" in 2017. In November 2017, the network "Stem Cell Research in Regenerative Medicine" (SCRM) joined the NTN biotechnet as full member and is heading together with Wyss Zurich the platform TCBM. The main objective of the TCBM platform is to foster exchange and collaborations between academic groups using and operating cleanrooms including bio-manufacturing products for translational clinical trials and/or standard therapies. The goal is to bundle the existing knowledge of experts in the area of compliant bio-manufacturing in order to optimise Good Manufacturing Practice (GMP)- production processes within an academic setting.
2. Platform members
The platform is led by Dr. Steffen M. Zeisberger and Prof. Eliane Müller and has multiple academic collaboration partners (please see and explore links under chapter 4).
2.1 How to become a TCBM-platform partner
To become a TCBM-platform partner, please contact Dr. Steffen M. Zeisberger or Prof. Eliane Müller for details. The partnership fees are:
Academy CHF 1'000.- p.a.
Spin-off company members CHF 1'500.- p.a.
industry members CHF 3'000.- p.a.
3. Events and News
Please visit events and news on this homepage